Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase III for Squamous Non-Small Cell Lung Cancer.

Nadunolimab is under clinical development by Cantargia and currently in Phase II for Squamous Non-Small Cell Lung Cancer.

This includes skin cancers like the following: Basal cell carcinoma (BCC) is the most common type of skin cancer. It starts in the top layer of the skin in cells called basal cells. Squamous cell ...

Opdivo Qvantig is approved for solid tumors, including melanoma, renal cell carcinoma, and non-small cell lung cancer. The ...

Shares of Bristol Myers Squibb ($BMY) were in the spotlight on Friday after the U.S. Food and Drug Administration approved an ...

The Food and Drug Administration announced it has approved nivolumab and hyaluronidase-nvhy, Opdivo Qvantig, from Bristol Myers (BMY) Squibb, ...